Biologics and Biosimilars

Drug Discovery and Clinical Applications
Artikelnummer: 978-1-138-59422-7
Einband: Fester Einband
Verfügbarkeit: POD-Titel lieferbar in 5 bis 10 Arbeitstagen
CHF 269.00
decrease increase

Biologics and Biosimilars: Drug Discovery and Clinical Applications is a systematic integration and evaluation of all aspects of biologics and biosimilars, encompassing research and development, clinical use, global regulation, and more. Biosimilars are biological therapeutic agents designed to imitate a reference biologic with high similarities in structure, efficacy, and safety, but also with potential clinical effective and cost-efficient options for the manufacturers, payers, clinicians, and patients. Most of the top-selling prescription drugs in the current market are biologics, which have revolutionized the treatment strategies and modalities for life-threatening and/or rare diseases. This book outlines the key processes and challenges in drug development, regulations, and clinical applications of biologics, biosimilars, and even interchangeable biosimilars. Global experts in the field discuss essential categories and prototype drugs of biologics and biosimilars in clinical practice such as allergenics, blood and blood components, cell treatment, gene therapy, recombinant therapeutic proteins or peptides, tissues, and vaccines. Additional features: Integrates the latest bench and bedside evidence of drug development and regulations of biologics and biosimilars Contains key study questions for each chapter to guide the readers, as well as drug charts for all therapeutic applications of biologics and biosimilars Presents detailed schematic illustrations to explain the drug development, clinical trials, regulations, and clinical applications of biologics and biosimilars This book is an invaluable tool for health care professional students, providers, and pharmaceutical and health care industries, as well as the public, providing readers with educational updates about the drug development and clinical affairs of biological medications and their similar drugs.

Biologics and Biosimilars: Drug Discovery and Clinical Applications is a systematic integration and evaluation of all aspects of biologics and biosimilars, encompassing research and development, clinical use, global regulation, and more. Biosimilars are biological therapeutic agents designed to imitate a reference biologic with high similarities in structure, efficacy, and safety, but also with potential clinical effective and cost-efficient options for the manufacturers, payers, clinicians, and patients. Most of the top-selling prescription drugs in the current market are biologics, which have revolutionized the treatment strategies and modalities for life-threatening and/or rare diseases. This book outlines the key processes and challenges in drug development, regulations, and clinical applications of biologics, biosimilars, and even interchangeable biosimilars. Global experts in the field discuss essential categories and prototype drugs of biologics and biosimilars in clinical practice such as allergenics, blood and blood components, cell treatment, gene therapy, recombinant therapeutic proteins or peptides, tissues, and vaccines. Additional features: Integrates the latest bench and bedside evidence of drug development and regulations of biologics and biosimilars Contains key study questions for each chapter to guide the readers, as well as drug charts for all therapeutic applications of biologics and biosimilars Presents detailed schematic illustrations to explain the drug development, clinical trials, regulations, and clinical applications of biologics and biosimilars This book is an invaluable tool for health care professional students, providers, and pharmaceutical and health care industries, as well as the public, providing readers with educational updates about the drug development and clinical affairs of biological medications and their similar drugs.

Schreiben Sie Ihre eigene Bewertung
  • Nur registrierte Benutzer können Produkte bewerten
*
*
Schlecht
Sehr gut
*
*
*
*
VerlagTaylor and Francis
EinbandFester Einband
Erscheinungsjahr2022
Seitenangabe510 S.
AusgabekennzeichenEnglisch
Abbildungenschwarz-weiss Illustrationen, farbige Illustrationen, Raster,schwarz-weiss, Raster, farbig, Zeichnungen, schwarz-weiss, Zeichnungen, farbig, Tabellen, schwarz-weiss
MasseH25.4 cm x B17.8 cm 1'240 g
CoverlagCRC Press (Imprint/Brand)
AutorFeng Xiaodong (Hrsg.) / Xie Hong-Guang (Hrsg.) / Malhotra, Ashim (Hrsg.) / Yang, Catherine F. (Hrsg.)

Über den Autor Feng Xiaodong (Hrsg.)

Xiaodong Feng, PhD, PharmD, began his biomedical research career 19 years ago in the Wound Healing Center, Stony Brook School of Medicine, Stony Brook, New York, USA. He then served for four years as assistant professor in the Department of Dermatology at the State University of New York at Stony Brook, USA. Currently, Dr. Feng is professor of Pharmacology and Oncology, and Associate Dean at California Northstate University College of Medicine, Elk Grove, USA; clinical pharmacist at Sutter Davis Hospital, California, USA; and oncology pharmacy specialist at Dignity Health Medical Foundation, Rancho Cordova, California, USA.Hong-Guang Xie, MD, PhD, earned his degrees from Central South University Xiangya School of Medicine, Changsha, China, was promoted to lecturer, and then to associate professor of pharmacology. Subsequently, he served as co-founder and associate director of the Pharmacogenetics Research Institute, Changsha, China; postdoctoral research fellow and faculty research instructor at Vanderbilt University, Nashville, Tennessee, USA; staff research fellow at the University of California Washington Center, DC, USA; and Oak Ridge Institute for Science and Education (ORISE) fellow for the United States Food and Drug Administration (US FDA). Dr. Xie is currently full professor of pharmacology and chief of the General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, China.

Weitere Titel von Feng Xiaodong (Hrsg.)

Produktbewertungen
Nur registrierte Benutzer können Produkte bewerten